Eric Shroff - Mar 1, 2025 Form 3 Insider Report for ABBOTT LABORATORIES (ABT)

Role
Senior Vice President
Signature
/s/ Eric Shroff by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Mar 1, 2025
Transactions value $
$0
Form type
3
Date filed
3/3/2025, 08:29 PM
Next filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABT Common shares without par value 32.5K Mar 1, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABT Option (right to buy) Mar 1, 2025 Common Shares 27K $75.90 Direct
holding ABT Option (right to buy) Mar 1, 2025 Common Shares 29K $87.72 Direct
holding ABT Option (right to buy) Mar 1, 2025 Common Shares 20K $124.04 Direct
holding ABT Option (right to buy) Mar 1, 2025 Common shares 20.4K $117.58 Direct
holding ABT Option (right to buy) Mar 1, 2025 Common shares 13.1K $106.24 Direct F1
holding ABT Option (right to buy) Mar 1, 2025 Common shares 13.3K $116.98 Direct F2
holding ABT Option (right to buy) Mar 1, 2025 Common shares 27.2K $135.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,352 on February 17, 2024, 4,352 on February 17, 2025, and 4,352 on February 17, 2026.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,416 on February 21, 2025, 4,417 on February 21, 2026, and 4,417 on February 21, 2027.
F3 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,075 on February 25, 2026, 9,076 on February 25, 2027, and 9,076 on February 25, 2028.